On September 28, 2021, the " Fifteenth China Listed Company Value Evaluation " list sponsored by Securities Times and co-organized by Caitong Securities was announced. There are a number of in vitro diagnosis companies were listed.

The purpose of this selection is to choose a group of companies that play a leading role in the capital market, including 100 listed companies on the Main Board, 50 listed companies on the ChiNext Board, and 10 listed companies on the SSE STAR Market.

The Securities Times launched the selection activity in May this year, mainly to the high-quality development of the capital market, support listed companies to enhance their competitiveness. The selection activity adheres to the principles of fairness, impartiality and openness, promotes the concept of value investment, and adheres to legal and compliant corporate governance standards. The selection is based on the overall performance of listed companies in creating wealth for investors, shareholders and themselves during the selection period and the past two years.